

Santen Pharmaceutical Co., Ltd.


# Status of Clinical Development

November 2, 2006

## Toshiaki Nishihata, Ph.D. Senior Corporate Officer Head of Research and Development Division

Forward-looking statements

The process of drug research and development from discovery to final approval and sales in long, complex and uncertain. Individual compounds are subject to a multitude of uncertainties, including the termination of clinical development at various stages and the non-approval of products after a regulatory filing has been submitted.



#### •DE-085 (Glaucoma, Ocular hypertension)

	Developr	_		
Region	As of Nov. 2, 2006 As of May 9, 2006 (Previous announcement)		Remarks	
Japan	Applied July 2006	Preparing for application	To be Launched in FY 2008	
Europe	Preparing for application	Preparing for application	To be filed in FY 2006	

USA	Deciding the possibility of NDA filing after careful study of its marketability
-----	---

Status of major clinical studies (ophthalmics): DE-089• DE-099

•DE-089 (Corneal and conjunctival epithelial disorders associated with dry eye)

	Development Stage		Remarks
Region As of Nov. 2, 2006		As of May 9, 2006 (Previous announcement)	
Japan	Start P3	Preparing P3	To be launched in FY2010

•DE-099 (Corneal and conjunctival epithelial disorders associated with dry eye)

	Development Stage		
Region	As of Nov. 2, 2006	As of May 9, 2006 (Previous announcement)	Remarks
Japan	Preparing P2	P1	Generic name: Gefarnate; preservative-free ointment

# Status of major clinical studies (ophthalmics and IOL): DE-101 MD-14

• DE-101 (Corneal and conjunctival epithelial disorders associated with dry eye)

	Development Stage		
Region	As of Nov 2, 2006	As of May 9, 2006 (Previous announcement)	Remarks
USA	P1	Preparing for P1	Generic name: Rivoglitazone

# • MD-14 (IOL)

	Development Stage		
Region As of Nov 2 2006		As of May 9, 2006 (Previous announcement)	Remarks
Japan	Approved	Preparing for application	US: preparing for application




#### •DE-092 (Glaucoma, Ocular hypertension)

Region	Stage	Result of clinical study
Japan	P2b	<ul> <li>Clear dose-response relationship was not seen</li> </ul>
USA	P2a	<ul> <li>Efficacy of IOP reduction was insufficient</li> </ul>

Clinical studies have been suspended

Future plan : Considering development options such as conducting with another dosage and/or different formulation, future plan to be decided within FY 2006



# •DE-096 ( RA, DME )

Region	Indication	Stage	Status	
Japan	RA	P2a	Conducting as	
	DMA	P2a	planned	



### • Clinical studies planned to start by June, 2007

Field	Dev. Code	Remarks	Origin
Retina	DE-102	Steroid DDS	Co-development with Oakwood, USA
Allergy	DE-103	PDE4 inhibitor	In-licensed from Ono, Japan
Glaucoma	DE-104	<b>ROCK</b> inhibitor	Co-development with Ube, Japan